Compare KALV & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KALV | ETW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2014 | 2005 |
| Metric | KALV | ETW |
|---|---|---|
| Price | $26.80 | $9.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.60 | N/A |
| AVG Volume (30 Days) | ★ 3.9M | 225.8K |
| Earning Date | 07-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000,000.00 | N/A |
| Revenue This Year | $185.42 | N/A |
| Revenue Next Year | $59.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $8.28 |
| 52 Week High | $26.85 | $9.60 |
| Indicator | KALV | ETW |
|---|---|---|
| Relative Strength Index (RSI) | 74.29 | 61.80 |
| Support Level | $14.22 | $9.11 |
| Resistance Level | $26.85 | $9.57 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.28 | 0.01 |
| Stochastic Oscillator | 76.47 | 93.62 |
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.